Finanzen von Achieve Life Sciences, Inc. (ACHV)ACHVAchieve Life Sciences, Inc.

Evaluating the bottom line, Achieve Life Sciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -844.99%, provide a clear picture of how effectively ACHV converts its operational activities into shareholder value.

In the context of the broader market, ACHV competes directly with industry leaders such as COLL and RIGL. With a market capitalization of $848.95M, it holds a significant position in the sector. When comparing efficiency, ACHV's gross margin of N/A stands against COLL's 55.18% and RIGL's 89.17%. Such benchmarking helps identify whether Achieve Life Sciences, Inc. is trading at a premium or discount relative to its financial performance.

The company has been experiencing significant net losses, with a net income of -74,769,000 USD in Q2 2026 and a forward P/E ratio of 35.34, indicating high expectations for future earnings despite current losses.